ProKidney Reports Full Year 2025 Financial Results and Business Highlights ProKidney (Nasdaq: PROK) reported full-year 2025 results and business highlights on March 18, 2026. Key points: $270.0M cash and marketable securities at year-end; positive Phase 2 REGEN-007 data; FDA alignment on an accelerated approval pathway using eGFR slope; Phase 3 PROACT 1 enrollment accelerating with pivotal readout expected Q2 2027.Management expects existing cash to fund operations into mid-2027 and plans BLA submission in Q4 2027 with potential approval and commercial launch in 2H 2028.

#PROK ProKidney Reports Full Year 2025 Financial Results and Business Highlights

www.stocktitan.net/news/PROK/pro-kidney-rep...

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025 More than half of the patients required for the Phase 3 REGEN-006 (PROACT 1) accelerated approval analysis using

#PROK ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

www.stocktitan.net/news/PROK/pro-kidney-rep...

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025 In patients with advanced chronic kidney disease (CKD) and diabetes, treatment with rilparencel resulted in statistically significant and clinically meaningful slowing of CKD progression Bilateral kidney injection with rilparencel resulted in a 4.6 mL/min/1.73m 2 (78%) improvement in the annual

#PROK ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025

www.stocktitan.net/news/PROK/pro-kidney-pre...

ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025 ProKidney (Nasdaq: PROK) will present two posters at the American Society of Nephrology Kidney Week 2025 in Houston, Nov 6–9, 2025. One is a late‑breaking poster reporting Phase 2 REGEN‑007 study results: "Renal Autologous Cell Therapy in Diabetes and CKD" (Session: Late‑Breaking Science Posters, Nov 6, 10:00 AM–12:00 PM CST, Board #TH‑PO1203). The second poster covers the inflammatory profile of the cell therapy candidate rilparencel (Session: Development, Stem Cells, and Regenerative Medicine, Nov 6, 10:00 AM–12:00 PM CST, Board #TH‑PO0575).Copies of both posters will be available on the company website after the event and abstracts are listed on the ASN Kidney Week program site.

#PROK ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025

www.stocktitan.net/news/PROK/pro-kidney-ann...

PRISM Mid-Day Movers
Consumer products lead today’s action:
#VNCE +90% on massive volume & wild swings
#WLDS +70% hitting highs near $10 before cooling

Other Movers:
#PROK +31%
#BITF +18%
#GMBL -30%

prismmarketview.com/prism-mid-da...

ProKidney Reports 78 Percent Gain in Q2 | The Motley Fool

#PROK #f4e2d52e-c75d-40ff-a0b3-068ae17be303 #data-news

Origin | Interest | Match

ProKidney's Breakthrough: FDA Backs Fast-Track Path as Kidney Treatment Shows Strong Phase 2 Results FDA confirms accelerated approval pathway for rilparencel using eGFR slope endpoint. Phase 2 trial shows 78% improvement in kidney function decline. Full data coming at ASN 2025. Learn more.

#PROK ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

www.stocktitan.net/news/PROK/pro-kidney-rep...

#PROK #68ddc3f2-faac-469b-a148-18fd51c68138 #investing

Origin | Interest | Match

#PROK #bed690f5-7d19-4c82-9a83-a582caacd3b6 #investing

Origin | Interest | Match

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Tue Jul 15th - #VNET #SBET #MGNX #LEU #IQ #DALN #CYCC #BMNR #BCTX #APLD #HIVE #WRD #RXRX #NVTS #QUBT #XAGE #SLDP #CPRT #IOVA #PROK - More: crystalequityresearch.com/SmCpStr/ - #smallcap

ProKidney Gains Regulatory Momentum as FDA Supports Accelerated Approval Pathway for Rilparencel ProKidney (PROK) has taken a step forward in its regulatory journey with the U.S. Food and Drug Administration formally aligning with the company’s proposed a

#PROK #ProKidney is gaining momentum! The FDA has backed an accelerated approval pathway for rilparencel, its lead therapy for chronic kidney disease—marking a major step toward regulatory success.
prismmarketview.com/prokidney-ga...

ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel ProKidney (Nasdaq: PROK) has achieved a significant regulatory milestone by securing FDA alignment on the accelerated approval pathway for rilparencel, its autologous cellular therapy for chronic kidney disease (CKD) patients with type 2 diabetes. The FDA confirmed that eGFR slope from the ongoing Phase 3 PROACT 1 trial can serve as the surrogate endpoint for accelerated approval.The FDA agreed that a rilparencel effect size of at least 1.5 mL/min/1.73m2/year improvement versus controls would demonstrate acceptable efficacy. Nearly half of the required patients for accelerated approval analysis have been enrolled, with topline data expected in Q2 2027. The PROACT 1 study will also serve as the confirmatory study for full approval.

#PROK ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel

www.stocktitan.net/news/PROK/pro-kidney-ann...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Mon Jul 14th - #EDHL #UMAC #DARE #PROK #ABVE #BMGL #HIVE #ONDS #YHC #SONN #RIG #SQFT #UMAC #WULF #AIFF #TDOC #SBET #RCAT #EOSE #BMNR #SRFM - More: crystalequityresearch.com/SmCpStr/ - #smallcap

PRISM Mid-Day Movers:
#DaréBioscience ( #DARE) soared 89%
#SolunaHoldings ( #SLNH) dropped 20%
Other PRISM Mid-Day Movers:
#CumberlandPharmaceuticals Inc. ( #CPIX) up 20.24%
#BitdeerTechnologiesGroup ( #BTCM) up 17.17%
#ProKidneyCorp. ( #PROK) down 15.42%

prismmarketview.com/prism-mid-da...

Ask the Elder: Why are there so many Korean Presbyterians? — Edgewater Presbyterian Church Korean churches went from receiving American missionaries to becoming mission leaders themselves.

Why are there so many Korean Presbyterians? She asked. I answer

@pcusa.bsky.social #kcpa #pck #prok

🚨 Institutions #optionsvolume surge detected! Weekly Top Momentum Activity from 🔥 INSIDERFINANCE.

🚨 Institutions #optionsvolume surge detected!

Weekly Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #PROK 2222.8x
2. #KDP 135.8x
3. #DT 115.5x
4. #IE 110.4x
5. #CNP 103.4x

#OptionFlow #OptionsTrading #Trading

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Thu Jul 10th - #RXRX #MREO #RUN #KLG #CIFR #AMPX #WULF #PROK #WOLF #IREN #BTCM #WRD #HIVE #HTZ #SQNS #MGNX #LEU #ISVLF #IQ #AVXL - More: crystalequityresearch.com/SmCpStr/ - #smallcap

ProKidney ($PROK) is making waves with rilparencel, a new therapy showing promise in chronic kidney disease treatment. Is this the breakthrough investors have been waiting for?
Read more 👉 buff.ly/xxKr3iy
#PROK #Biotech #DrugDevelopment #ValueTheMarkets

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Wed Jul 9th - #RIG #RXRX #IREN #CIFR #BTBT #SRFM #EVOK #VLRS #MBIO #SOBR #TOI #SBET #PROK #MLGO #LEU #HUT #GAME #VOR #CLDI #HIVE - More: crystalequityresearch.com/SmCpStr/ - #smallcap

#ProKidney #PROK currently leads the PRISM Emerging Biotech Index. Shares are trading up ~50% today and 730% this week following positive Phase 2 trial results. The company will be presenting at H.C. Wainwright Kidney Conference July 14th.

Learn more here: bit.ly/44T9Hb5

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #SAP 15.7x
2. #PROK 13.3x
3. #DVN 9.3x
4. #FINV 4.7x
5. #CORZ 4.1x

#OptionFlow #OptionsTrading #Trading

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Tue Jul 8th - #PROK #SAND #RIG #SBET #CIFR #BSLK #RUN #NDRA #HIVE #SRFM #PCT #MGNX #LEU #IQ #CERS #CLOV #TGB #BGLC #VOR #IREN - More: crystalequityresearch.com/SmCpStr/ - #smallcap

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with improving money flow, Tue Jul 8th - #HIFS #GAME #FTFT #CVAC #BWMN #API #CARS #BUR #ARMN #ICCM #LGVN #NBBK #OBLG #PROK #RWAY #SNWV #TLRY #WKHS - More: crystalequityresearch.com/SmCpStr/ - #smallcap

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #WOLF 61% OTM
2. #CORZ 44% OTM
3. #PROK 39% OTM
4. #CRCL 27% OTM
5. #GME 25% OTM

#OptionFlow #OptionsTrading #Trading

Tuesday's Top 6 Runners Gainers < $10.00 (July 08, 2025) are: $PROK $3.73 (543%), $NDRA $8.3 (136%), $BTCS $5.91 (127%), $IROH $10.07 (65%), $ENTO $0.53 (64%), $SOBR $3.37 (62%) #PROK #pennystocks #wealth #tradethewave

News; ( NASDAQ: #PROK ) ProKidney Surges After Positive Phase 2 Results for Chronic Kidney Disease Therapy

News; ( NASDAQ: #PROK ) Elite Eight Stocks to Watch - July 8, 2025

ProKidney Surges After Positive Phase 2 Results for Chronic Kidney Disease Therapy Shares of ProKidney (PROK) soared more than 580% today following the release of encouraging topline results from its Phase 2 REGEN-007 clinical trial evaluating

ProKidney Shares Surge on Positive CKD Trial Results
#ProKidney ( #PROK) is making waves after reporting encouraging Phase 2 results for its chronic kidney disease therapy, driving investor optimism and momentum in renal innovation.
prismmarketview.com/prokidney-su...

Just In: ( NASDAQ: #PROK ) Ten Trades to Watch July 8, 2025